Log In
Print
BCIQ
Print
Print this Print this
 

Kynamro, mipomersen (ISIS 301012, ISIS 301012 subcutaneous)

  Manage Alerts
Collapse Summary General Information
Company Isis Pharmaceuticals Inc.
DescriptionSecond-generation antisense inhibitor of Apolipoprotein B-100 (APOB-100) mRNA
Molecular Target Apolipoprotein B-100 (APOB-100) mRNA
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentApproved
Standard IndicationHypercholesterolemia
Indication DetailsTreat apheresis-eligible hypercholesterolemia patients; Treat familial hypercholesterolemia (FH); Treat heterozygous familial hypercholesterolemia (HeFH); Treat high-cholesterol patients at high risk for coronary heart disease; Treat high-risk hypercholesterolemia; Treat homozygous familial hypercholesterolemia (hoFH); Treat hypercholesterolemia; Treat severe high cholesterol; Treat severe hypercholesterolemia
Regulatory Designation

U.S. - Standard Review (Treat homozygous familial hypercholesterolemia (hoFH))

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today